- Home
- FENC vs FATE Comparison
FENC vs FATE Comparison
Compare FENC & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- FATE
- Stock Information
- Founded
- FENC 1996
- FATE 2007
- Country
- FENC United States
- FATE United States
- Employees
- FENC N/A
- FATE N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FENC Health Care
- FATE Health Care
- Exchange
- FENC Nasdaq
- FATE Nasdaq
- Market Cap
- FENC 156.9M
- FATE 133.0M
- IPO Year
- FENC 2001
- FATE 2013
- Fundamental
- Price
- FENC $8.07
- FATE $1.30
- Analyst Decision
- FENC Strong Buy
- FATE Hold
- Analyst Count
- FENC 2
- FATE 8
- Target Price
- FENC $13.00
- FATE $4.14
- AVG Volume (30 Days)
- FENC 105.2K
- FATE 1.8M
- Earning Date
- FENC 05-13-2025
- FATE 05-13-2025
- Dividend Yield
- FENC N/A
- FATE N/A
- EPS Growth
- FENC N/A
- FATE N/A
- EPS
- FENC N/A
- FATE N/A
- Revenue
- FENC $30,912,000.00
- FATE $13,335,000.00
- Revenue This Year
- FENC N/A
- FATE N/A
- Revenue Next Year
- FENC $58.65
- FATE N/A
- P/E Ratio
- FENC N/A
- FATE N/A
- Revenue Growth
- FENC N/A
- FATE 105.85
- 52 Week Low
- FENC $3.96
- FATE $0.66
- 52 Week High
- FENC $8.56
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- FENC 66.93
- FATE 57.89
- Support Level
- FENC $7.79
- FATE $1.21
- Resistance Level
- FENC $8.34
- FATE $1.38
- Average True Range (ATR)
- FENC 0.46
- FATE 0.12
- MACD
- FENC 0.06
- FATE 0.02
- Stochastic Oscillator
- FENC 76.75
- FATE 82.36
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.